Gang Shu, Jingyi Han, Yuanling Huang, Cong Huang, Liping Kong, Hongchang Li, Lu Zhao, Qijiang Tang, Jia Li, Yingnan Liu, Jingyi Liu, Hongjun Chen, Zongyan Chen
Accepted: 2024-12-10
Infectious Bursal Disease (IBD) is an acute, highly contagious disease that affects chicks (MüLler et al. 2003). IBD mainly damages the immune organs of chicks, especially the central immune organ, causing immune suppression in diseased chicks (MULLER et al, 2012). The pathogenic Infectious Bursal Disease virus (IBDV) is a member of the Avira virus genus in the Birnaviridae family. (Dobos et al, 1979; Müller et al, 1979; Harkness et al, 1975). IBDV is prevalent worldwide, causing serious economic losses to the global poultry industry. Currently, vaccination remains the most cost-effective way to prevent IBDV.
Subunit vaccines are based on specific components of pathogens and are typically located on their surface. Therefore, subunit vaccines are considered safer than completely pathogen based inactivated or attenuated live vaccines. VP2 protein is the main host protective antigen that contains most neutralizing sites and is the target protein for developing subunit vaccines using various expression systems. Nowadays, IBDV is widely prevalent, but commercial vaccines are no longer effective in preventing it. It is suspected that it is related to genetic changes in the VP2 gene, causing immune escape. Therefore, in this experiment, IBDV variant strain isolated in the laboratory was used to prepare IBDV subunit vaccine to protect sensitive chicks from IBDV infection.
Adjuvants can enhance the immunogenicity of antigens and enhance their immune efficacy. With the development of biotechnology and the upgrading of vaccines, adjuvants have become an important part of improving vaccine quality. Montanide™ ISA 78 VG is an oil in water adjuvant enhanced by immunostimulatory compounds. Its ingredients are based on fortified oil, which can induce antigen-specific cell-mediated immune responses, thereby enhancing protection against viral diseases. MONTANIDE™ GEL is a semi transparent flowable gel with good and stable fluidity. It is easy to mix the antigen phase and adjuvant, and easy to prepare with low viscosity. Aluminum hydroxide adjuvant is the oldest used vaccine adjuvant and remains the primary adjuvant in animal vaccines to this day. This study selected IBDV VP2 protein as the immunogen and combined it with three adjuvants, while comparing it with the widely used white oil adjuvant. By immunizing chicks and comparing the effects of different adjuvants on immune protection, this provides a reference for the development of universal IBDV vaccines.
The IBDV VP2 protein was successfully expressed in E. coli through a prokaryotic expression system, and the protein exists in the form of inclusion bodies. The BCA method was used to detect the protein concentration, which was determined to be 1.5 mg mL-1 by the BCA assay kit. The IBDV VP2 subunit was emulsified with MontanideTM ISA 78 VG, MontanideTM Gel P, Aluminium hydroxide (Seppic Shanghai Chemical Specialities Co., China), and white oil (ExxonMobil, China) adjuvantat a ratio of 3:7, 9:1, 9:1 and 1:1 (w/v) , while ensuring the same antigen content to produce the IBDV VP2 subunit vaccines. IBDV VP2 subunit vaccines without adjuvant also were compared and PBS was served as control. The preparation methods of each vaccine group were shown in Appendix C.
The chicks without specific-pathogens-free (SPF) provided by Zhejiang Lihua Agricultural Technology Co., Ltd were subdivided into six immunized groups. The grouping of chicks and the proportion of adjuvants were shown in Table 1. All of the chicks were subcutaneously vaccinated into their necks. Primary vaccination was given on day 7, and revaccination was given on day 14. At 28 days of age, half of the chicks in each group were separated and infected with 0.2 mL of IBDV-LY21/2 (1×106 EID50 0.1mL-1) (Huang et al, 2023). The positive control group was not vaccinated but was infected, and six infection groups were established thereafter.
During the immunization process, it was observed that the Gel P, Adjuvant-free and PBS control groups' vaccines were fully absorbed 1 minute after injection, partially absorbed at intermediate dosage in ISA 78 VG, Aluminium hydroxide, not absorbed in White oil. Within 48 h after injection, there was redness, warmth and swelling at the injection site in White oil. Within 5 days after injection into GroupIII-white oil, the reaction at the injection site got better and disappeared on its own. In addition, the weight gain trend of chicks in different injection groups was similar, indicating that vaccination had no significant effect on weight gain of chicks.
The clinical reactions of experimental animals after infection induced by IBDV, including virus shedding, morphometric identification, and gross lesions, were shown in Figure 1-A. There is no gross clinical symptoms or mortality of vaccinated chicks after challenged by IBDV. All the unvaccinated animals succumbed to the disease within 10 days post-challenge (dpc) and caused atrophy of the cloacal bursa. After calculating the group's bursa index for virus attack after immunization (Sharma et al., 1989; Lucio & Hitchner, 1979) , the results showed that the BBIX of the ISA 78 VG, Gel P, and Aluminum hydroxide groups were greater than 0.7. Although the BBIX of the white oil and Adjuvant-free groups were greater than 0.7, the BBIX was significantly smaller than the above three groups, and the BBIX of the positive control group was less than 0.7. After 10 days of post-immunization challenge, there were no significant pathological changes in the bursa in the ISA 78 VG, Gel P, and Aluminum hydroxide groups compared to the Negative control group. In the positive control group, there were significant lesions in the bursa with atrophy of the bursa (Figure 1-B). This proved that the vaccine prepared in this experiment can inhibit the atrophy of the chicken's bursa and had a preventive effect on chickens infected with IBDV.
The immune efficacy of IBDV VP2 subunit vaccines prepared with different adjuvants was evaluated. Serum collected on day 7 after the prime-boost manner and on days 7, 14, and 21 after the second dose were detected using indirect ELISA method. The percentage of antibodies in the serum of the ISA 78, GLP, and Aluminum hydroxide groups can detect high antibody levels on the 7th day after the first immunization, and positive antibodies can still be detected on the 28th day after secondary immune enhancement. The white oil group achieved an antibody-positive rate of 80% on the 14th day after secondary immune enhancement. The adjuvant-free group only detected antibodies with a 50% positive rate at the end of the experiment and continued to decrease antibody levels (Figure 1-C).
According to the statistical results of the cell neutralization experiment of each immune group at 96 h p.i., it can be observed that on the 7th day after the first immunization, only the adjuvant-free group did not achieve a neutralization titer of 1:16. The results showed that the neutralizing antibody production time in this experiment was earlier than the antibody production time previously studied, which was 14 days after immunization (Li et al, 2020). On the 7th day after the second immunization, the neutralizing titers of all groups significantly increased. On the 21st day after immunization, the antibody level reached its highest, with the Aluminum hydroxide group having the highest neutralizing antibody level. On the 28th day after immunization, the neutralizing titer of the adjuvant-free group decreased to 1:16, while the antibody level of the ISA 78 VG, Gel P, and Aluminum hydroxide groups remained at a high level. The level of neutralizing antibodies was shown in Figure 1-C.
The IL-2 ELISA detection kit was used to detect IL-2 levels, and the results showed that ISA 78 VG, Gel P, and Aluminum hydroxide groups could produce higher levels of IL-2 (Figure 1-D).
IBDV replication following challenge exposure of the experimental animals was summarized in Figure 7. The total viral RNA of IBDV from bursa tissues of chicks at day 10 post infected with the LY21/2 strain of IBDV, and viral loads were determined by qRT-PCR technique. The vaccine's efficacy in preventing virus isolation from swabs was consistent with tissue samples. Compared to the control group, the number of viral RNA copies is the lowest in the ISA 78 VG group among the immunization groups. The collected pharyngeal and anal swabs of chicks were used to detect detoxification, and the results showed that ISA 78 VG group had the lowest detoxification level, with the GLP group being the second lowest. ISA 78 VG, Gel P, white oil, and Aluminum hydroxide could reduce virus infection in chicks (XIONG et al, 2013) (Fig. 1-E).
In order to evaluate the pathological changes caused by IBDV infection, paraffin sections were prepared for H&E staining and tunel detection of all bursa tissues. The VP2 subunit vaccine prepared with three adjuvants had normal bursa structure, while some follicles in the white oil and Adjuvant-free groups showed atrophy and vacuolization. The positive control group showed a decrease in lymphocytes, infiltration of macrophages, atrophy of follicles, and proliferation of connective tissue. Tunel detection showed that the ISA 78 VG, Aluminium hydroxide, and Gel P groups showed less apoptosis in the bursa, while the white oil and Adjuvant-free groups showed significant apoptosis with green fluorescence . Indicating that the prepared vaccine had a protective effect on the bursa and had not caused any damage to the bursa (Figure 1-F).
This experiment provides preliminary information on the duration of protection that vaccination can provide for chicks. The safety and efficacy of subunit vaccines prepared with different adjuvants and without adjuvant were evaluated on chicks. Under the same dose of antigen (IBDV), the protective effects of ISA 78 VG, Gel P, and Aluminum hydroxide adjuvants evaluated were enhanced to prevent infection with this pathogen. To confirm whether ISA 78 VG and Aluminum hydroxide can effectively reduce antigen load, long-term evaluation is necessary. A previous study showed that classical strain vaccines can completely prevent classical strain infections, but can only provide partial protection against nVarIBDV (Eterradossi et al, 2020). nVarIBDV strain vaccines can not only provide complete immune protection against homologous nVarIBDV, but also against heterologous vvIBDV variant strains (Wang et al, 2021). The immune protection level of the VP2 protein subunit vaccine prepared in this experiment against other strains have not been studied and further research is needed.